(2022) An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. FRONTIERS IN IMMUNOLOGY. ISSN 1664-3224 J9 - FRONT IMMUNOL
Full text not available from this repository.
Abstract
Human papillomavirus (HPV) is the most common sexually transmitted agent worldwide. Early prevention with HPV vaccination is a safe and effective method against this disease. HPV vaccines provided more protection against several oncogenic HPV strains. Three prophylactic HPV vaccines have been approved to target high-risk HPV types and protect against HPV-related disorders. These existing vaccines are based on the recombinant DNA technology and purified L1 protein that is assembled to form HPV empty shells. The prophylactic vaccines are highly immunogenic and can induce production of specific neutralizing antibodies. However, therapeutic vaccines are different from these prophylactic vaccines. They induced cell-mediated immunity against transformed cells, instead of neutralizing antibodies. The second generation of prophylactic HPV vaccines, made from alternative viral components using cost-effective production strategies, is undergoing clinical evaluation. The purpose of this review is to provide a complete and up-to-date review of the types of HPV vaccines and the efficiency of each of them for readers.
Item Type: | Article |
---|---|
Keywords: | human papillomavirus (HPV) vaccines HPV vaccination cervical cancer prevalence (HPV)-16/18 AS04-ADJUVANTED VACCINE 9-VALENT HPV VACCINE CERVICAL-CANCER ADVISORY-COMMITTEE PARTICLE VACCINE INTRAEPITHELIAL NEOPLASIA SUSTAINED EFFICACY RISK-FACTORS TA-GW INFECTION |
Journal or Publication Title: | FRONTIERS IN IMMUNOLOGY |
Journal Index: | ISI |
Volume: | 12 |
Identification Number: | https://doi.org/10.3389/fimmu.2021.805695 |
ISSN: | 1664-3224 J9 - FRONT IMMUNOL |
Depositing User: | Zahra Otroj |
URI: | http://eprints.mui.ac.ir/id/eprint/15913 |
Actions (login required)
View Item |